Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Amortization of Deferred Charges (2020 - 2025)

Historic Amortization of Deferred Charges for Kymera Therapeutics (KYMR) over the last 6 years, with Q3 2025 value amounting to -$2.2 million.

  • Kymera Therapeutics' Amortization of Deferred Charges rose 3960.81% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.1 million, marking a year-over-year increase of 1571.96%. This contributed to the annual value of -$14.0 million for FY2024, which is 16741.25% down from last year.
  • Per Kymera Therapeutics' latest filing, its Amortization of Deferred Charges stood at -$2.2 million for Q3 2025, which was up 3960.81% from -$2.1 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Amortization of Deferred Charges peaked at $1.7 million during Q3 2021, and registered a low of -$4.0 million during Q2 2024.
  • Over the past 5 years, Kymera Therapeutics' median Amortization of Deferred Charges value was -$1.3 million (recorded in 2023), while the average stood at -$1.0 million.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first crashed by 199827.59% in 2023, then soared by 4725.19% in 2025.
  • Over the past 5 years, Kymera Therapeutics' Amortization of Deferred Charges (Quarter) stood at $1.6 million in 2021, then crashed by 155.32% to -$905000.0 in 2022, then plummeted by 40.22% to -$1.3 million in 2023, then plummeted by 157.45% to -$3.3 million in 2024, then soared by 33.03% to -$2.2 million in 2025.
  • Its Amortization of Deferred Charges stands at -$2.2 million for Q3 2025, versus -$2.1 million for Q2 2025 and -$2.5 million for Q1 2025.